ClinicalTrials.gg
CompletedNCT05139030Updated Oct 24, 2024Results posted

Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty

A Phase 3 interventional study of bupivacaine liposome injectable suspension and Bupivacaine Hydrochloride in Knee Osteoarthritis and Pain Management, sponsored by Pacira Pharmaceuticals, Inc. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc. — 2 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Pacira BioSciences, Inc..

Enrollment
6th of 15
167 · median 135
Started
2022
the only one that year
Phase 3
4 of 16
none open now
Registered
14th of 16
by date

Among the 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc., this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 4 in phase 3, and was the 14th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Osteoarthritis, Knee by Pacira BioSciences, Inc., or all of them as a file.
02

Study summary

The purpose of the study is to compare magnitude of postsurgical analgesic effect in different groups following a single dose of study drug when administered via adductor canal block in subjects undergoing primary unilateral total knee arthroplasty.

Read the detailed description

This is a Phase 3, multicenter, randomized, double-blind, active-controlled study in approximately 160 subjects undergoing primary unilateral TKA under spinal anesthesia. The study will have 2 cohorts, enrolling in parallel.

Cohort 1 -Pharmacokinetics (PK), pharmacodynamics (PD), Efficacy, and Safety, Cohort 2 -Efficacy and Safety

An adaptive study design will be used in this study. An interim analysis to evaluate the sample size assumptions and evaluate futility will occur when a total of approximately 80 subjects (40 subjects in each arm) combined from either Cohort 1 or Cohort 2 have enrolled and provided complete assessment data for the primary efficacy outcome.

The time from study drug administration until the end of participation is Post-operative day (POD) 14 (±3 days). Therefore, subjects may participate in the study for up to 62 days.

03

Conditions studied

  • Knee Osteoarthritis
  • Pain Management

Keywords

  • EXPAREL
  • bupivacaine
  • analgesic
  • Adductor Canal Block
  • TKA
  • knee arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, ages 18 or older at screening.
  2. Indicated to undergo primary unilateral total knee arthroplasty under spinal anesthesia.
  3. Primary indication for TKA is degenerative osteoarthritis of the knee.
  4. (ASA) physical status 1, 2, or 3.
  5. Able to provide , adhere to the study schedule, and complete all study assessments.
  6. (BMI) ≥18 and \<40 kg/m2.

Exclusion criteria

Exclusion Criteria:

  1. Allergy, , intolerance, or to any of the study medications for which an alternative is not named in the protocol (e.g., amide-type local anesthetics, opioids, bupivacaine HCl, NSAIDs).
  2. Planned concurrent surgical procedure (e.g., bilateral TKA).
  3. Undergoing unicompartmental TKA or revision TKA.
  4. Concurrent painful physical condition (e.g., arthritis, fibromyalgia, cancer) that may require analgesic treatment with NSAIDs or opioids in the post dosing period for pain that is not strictly related to the knee surgery and which, in the Investigator's opinion, may confound the post dosing assessments.
  5. Inadequate sensory function below the knee as assessed by the Investigator.
  6. History of contralateral TKA within 1 year.
  7. Previous open knee surgery on the knee being considered for TKA. Prior arthroscopy is permitted.
  8. History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  9. Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  10. Previous participation in an EXPAREL study.
  11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, could interfere with study assessments or compliance.
  12. Currently pregnant, nursing, or planning to become pregnant during the study.
  13. medical disease that, in the opinion of the Investigator, would make participation in a clinical study inappropriate. This includes diabetic neuropathy, coagulation or bleeding disorders, severe peripheral vascular disease, renal insufficiency, hepatic dysfunction, or other conditions that would constitute a contraindication to participation in the study.
  14. Currently on a neuromodulating agent (e.g., gabapentin, pregabalin [Lyrica], duloxetine [Cymbalta], etc.)].
  15. Current use of systemic within 30 days of randomization in this study.
  16. Use of dexmedetomidine HCl (Precedex®) or clonidine within 3 days of study drug administration.
  17. Any use of marijuana [including Tetrahydrocannabinol (THC) and Cannabidiol (CBD)] within 30 days prior to randomization, or planned use during the course of the study.
  18. Chronic opioid use (average ≥30 oral morphine equivalents/day) within 30 days prior to randomization.

Given the coronavirus disease 2019 (COVID-19) pandemic, if there is a concern about a subject's recent or potential exposure to COVID-19, or if the subject is not medically fit/cleared for surgery due to suspected COVID-19 illness/symptoms, the subject must be excluded per Exclusion criterion #13.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Cohort 1: EXPAREL admix arm

    subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl

    Drug: bupivacaine liposome injectable suspension

  • Active comparator
    Cohort 1: Bupivacaine HCl arm

    subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline

    Drug: Bupivacaine Hydrochloride

  • Experimental
    Cohort 2: EXPAREL admix arm

    subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL admixed with 10 mL (50 mg) 0.5% bupivacaine HCl

    Drug: bupivacaine liposome injectable suspension

  • Active comparator
    Cohort 2: Bupivacaine HCl arm

    subjects randomized to this treatment arm will receive 10 mL (50 mg) 0.5% bupivacaine HCl mixed with 10 mL normal saline

    Drug: Bupivacaine Hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. NRS Scores Through 96 Hours Post-surgery

    The numeric rating scale pain intensity scores ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 96 hours post-surgery. For each subject, the area under the curve was derived using the trapezoidal rule on the pain scores adjusted for opioid pain medication using the observed and imputed values. Area under the curve started with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 96 hours post-surgery. Pain scores were taken at 5 interval point: 0 hours, 24 hours, 48 hours, 72 hours, and 96 hours. There were also unscheduled pain scores measured before opioid consumption also included in the area under the curve calculation. The area under the curve ranged from 0 to 960. Higher scores represent a worse outcome.

    Time frame: 0 to 96 hours post-surgery

Secondary outcomes

  1. Postsurgical Opioid Consumption Through 96 Hours Post-surgery

    Total postsurgical opioid consumption in mg oral morphine equivalents (OMED) from 0 to 96 hours post-surgery.

    Time frame: 0 to 96 hours post-surgery

  2. Time to First Opioid

    Time to first opioid consumption post-surgery

    Time frame: 0 to 96 hours post-surgery

  3. NRS Scores

    Worst and average NRS pain intensity scores at 24h, 48h, 72h and 96h from the end of surgery Worst and average pain intensity scores on a numeric rating scale ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours. Mean scores at each timepoint are provided. The total range is 0 (no pain) to 10 (worst possible pain). Higher values on the scale represent worst outcome

    Time frame: 0-24hours, 24-48hours, 48-72hours, 72-96hours

07

Results

Posted Oct 24, 2024

Participant flow

Participants were recruited based on physician referral at 6 sites between January 2022 and July 2022. The first participant was enrolled on January 18, 2022 and the last participant was enrolled in June 08, 2022.

Participant flow — Overall Study
MilestoneCohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl Arm
Started8582
Completed8477
Not completed15
Withdrew: Withdrawal by subject13
Withdrew: Adverse event01
Withdrew: Failure to meet continuation criteria01

Outcome measures

PrimaryNRS Scores Through 96 Hours Post-surgery

The numeric rating scale pain intensity scores ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 96 hours post-surgery. For each subject, the area under the curve was derived using the trapezoidal rule on the pain scores adjusted for opioid pain medication using the observed and imputed values. Area under the curve started with the first pain assessment obtained after surgery and use all subsequent pain assessments up to 96 hours post-surgery. Pain scores were taken at 5 interval point: 0 hours, 24 hours, 48 hours, 72 hours, and 96 hours. There were also unscheduled pain scores measured before opioid consumption also included in the area under the curve calculation. The area under the curve ranged from 0 to 960. Higher scores represent a worse outcome.

Time frame:
0 to 96 hours post-surgery
Reported as:
Mean · units on a scale*hours
NRS Scores Through 96 Hours Post-surgery
units on a scale*hoursCohort 1 + 2 EXPAREL ADMIX ARMCohort 1 + 2 BUPIVACAINE HCI ARM
NRS Scores Through 96 Hours Post-surgery594.4 ± 191.65650.1 ± 178.95
Statistical analysis
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0074 · Mean difference (final values): -65.8 · 95% CI -118.7 to -12.9Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
SecondaryPostsurgical Opioid Consumption Through 96 Hours Post-surgery

Total postsurgical opioid consumption in mg oral morphine equivalents (OMED) from 0 to 96 hours post-surgery.

Time frame:
0 to 96 hours post-surgery
Reported as:
Geometric mean · milligrams oral morphine equivalents
Postsurgical Opioid Consumption Through 96 Hours Post-surgery
milligrams oral morphine equivalentsCohort 1 + 2 EXPAREL ADMIX ARMCohort 1 + 2 BUPIVACAINE HCI ARM
Postsurgical Opioid Consumption Through 96 Hours Post-surgery109.19 ± 54.420136.91 ± 48.284
Statistical analysis
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0018 · Mean ratio: 0.77 · 95% CI 0.64 to 0.92Total opioid consumption was transformed to log scale. Main effect of treatment, covariates: pooled Investigator site (categorical); age (continuous)
SecondaryTime to First Opioid

Time to first opioid consumption post-surgery

Time frame:
0 to 96 hours post-surgery
Reported as:
Median · hours
Time to First Opioid
hoursCohort 1 + 2 EXPAREL ADMIX ARMCohort 1 + 2 BUPIVACAINE HCI ARM
Time to First Opioid4.15 (3.80 to 4.83)3.63 (2.98 to 4.05)
Statistical analysis
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · Cox proportional hazards model · p = 0.0127 · Hazard ratio (hr): 0.70 · 95% CI 0.51 to 0.96Cox proportional hazard model: treatment as main effect, pooled Investigator site as categorical, and age and height as continuous covariates
SecondaryNRS Scores

Worst and average NRS pain intensity scores at 24h, 48h, 72h and 96h from the end of surgery Worst and average pain intensity scores on a numeric rating scale ranging from 0 to 10, where 0 equals no pain and 10 equals the worst possible pain, from 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours. Mean scores at each timepoint are provided. The total range is 0 (no pain) to 10 (worst possible pain). Higher values on the scale represent worst outcome

Time frame:
0-24hours, 24-48hours, 48-72hours, 72-96hours
Reported as:
Mean · units on a scale
NRS Scores
units on a scaleCohort 1 + 2 EXPAREL ADMIX ARMCohort 1 + 2 BUPIVACAINE HCI ARM
Worst pain at 24 hours8.6 ± 1.638.7 ± 1.77
Worst pain at 48 hours7.9 ± 1.988.2 ± 1.81
Worst pain at 72 hours6.8 ± 2.337.5 ± 2.14
Worst pain at 96 hours6.6 ± 2.247.0 ± 2.34
Average pain at 24 hours6.7 ± 1.896.6 ± 2.00
Average pain at 48 hours5.8 ± 2.036.2 ± 1.84
Average pain at 72 hours5.2 ± 2.145.7 ± 2.08
Average pain at 96 hours4.8 ± 2.185.2 ± 1.96
Statistical analysis
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.3674 (Worst pain 0-24 hours) · Least square mean difference: -0.1 · 95% CI -0.6 to 0.4Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.1016 (Worst pain 24-48 hours) · Least square mean difference: -0.4 · 95% CI -0.9 to 0.2Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0215 (Worst pain 48-72 hours) · Least square mean difference: -0.7 · 95% CI -1.4 to -0.0Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0794 (Worst pain 72-96 hours) · Least square mean difference: -0.5 · 95% CI -1.2 to 0.2Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.3606 (Average pain 0-24 hours) · Least square mean difference: -0.1 · 95% CI -0.7 to 0.5Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0184 (Average pain 24-48 hours) · Least square mean difference: -0.6 · 95% CI -1.1 to -0.0Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0476 (Average pain 48-72 hours) · Least square mean difference: -0.5 · 95% CI -1.1 to 0.1Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age
  • Cohort 1 + 2 EXPAREL ADMIX ARM vs Cohort 1 + 2 BUPIVACAINE HCI ARM · ANCOVA · p = 0.0529 (Average pain 72-96 hours) · Least square mean difference: -0.5 · 95% CI -1.1 to 0.1Main effect of treatment, categorical covariate of pooled Investigator site, and continuous covariates of age

Adverse events

Collected over Treatment-emergent adverse events were collected from the date and time on or after the start date and time of study drug administration through post-operative Day 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 + 2 EXPAREL ADMIX ARM0/85 (0%)3/85 (3.5%)77/85 (90.6%)
Cohort 1 + 2 BUPIVACAINE HCI ARM0/81 (0%)3/81 (3.7%)71/81 (87.7%)
Most frequent serious events
Most frequent serious events
EventCohort 1 + 2 EXPAREL ADMIX ARMCohort 1 + 2 BUPIVACAINE HCI ARM
Acute myocardial infarctionCardiac disorders0/851/81
Atrial fibrillationCardiac disorders0/851/81
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/851/81
AngioedemaSkin and subcutaneous tissue disorders0/851/81
TachycardiaCardiac disorders1/850/81
PneumoniaInfections and infestations1/850/81
Post procedural haematomaInjury, poisoning and procedural complications1/850/81
Most frequent other events
Most frequent other events
EventCohort 1 + 2 EXPAREL ADMIX ARMCohort 1 + 2 BUPIVACAINE HCI ARM
NauseaGastrointestinal disorders34/8530/81
ConstipationGastrointestinal disorders30/8531/81
InsomniaPsychiatric disorders5/8513/81
HeadacheNervous system disorders13/852/81
Muscle spasmsMusculoskeletal and connective tissue disorders11/859/81
HypotensionVascular disorders3/858/81
VomitingGastrointestinal disorders5/856/81
PruritusSkin and subcutaneous tissue disorders6/854/81
TachycardiaCardiac disorders4/855/81
HypertensionVascular disorders5/854/81

Baseline characteristics

Number of all participants for whom baseline characteristics were measured, in each cohort and in the entire study population (total)

Age, Categorical
Age, Categorical(Participants)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
<=18 years000
Between 18 and 65 years5453107
>=65 years312859
Age, Continuous
Age, Continuous(years)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
Mean62.00 ± 7.04962.21 ± 8.40262.10 ± 7.716
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
Female423981
Male434285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
Hispanic or Latino211233
Not Hispanic or Latino6466130
Unknown or Not Reported033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
Race — White6763130
Race — Black/African American141529
Race — Other437
Region of Enrollment
Region of Enrollment(participants)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
United States8581166
ASA classification
ASA classification(Participants)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
ASA 1212142
ASA 26256118
ASA 3235
Unknown011
Body Mass Index
Body Mass Index(kilograms/m^2)Cohort 1 + 2: EXPAREL Admix ArmCohort 1 + 2: Bupivacaine HCl ArmTotal
Mean31.43 ± 4.78632.74 ± 4.95532.07 ± 4.899

3 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Lotus Clinical Research
    Pasadena, California 91105, United States
  • Midwest Clinical Research Center, LLC
    Dayton, Ohio 45417, United States
  • First Surgical Hospital
    Bellaire, Texas 77401, United States
  • HD Research- Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jul 2022, 5 months.

Results were first posted in Oct 2024, 2 years 3 months after primary completion.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 5 months is below that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Dec 1, 2021
StartActual
Jan 18, 2022
Primary completionActual
Jul 11, 2022
CompletionActual
Jul 11, 2022
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05139030
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Jan 18, 2022
Primary completion
Jul 11, 2022
Completion
Jul 11, 2022
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Study contacts

Gary Nevins
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion